HealthQuill mRNA
The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between 18 and 59 years.
Drugs Health Pharma

US regulator gives nod for Moderna’s expanded use of mRNA vaccine

HQ Team June 13, 2025: The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between.

Read More
Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in an all-stock deal to expand the former’s mRNA-based cancer immunotherapy candidates.
Drugs Health Pharma

BioNTech SE to acquire CureVac for $1.25 billion in all-stock deal

HQ Team June 12, 2025: Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in.

Read More
Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or melanoma.
Drugs Health Pharma

Moderna, Merck’s skin cancer vaccine shows rise in survival rates

Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or.

Read More
More than 35 million people may have cancer in 2050 — an increase of 77% from 20 million new cases in 2022, according to a WHO report.
Drugs Health Medical

Novel mRNA vaccine shows promise in treating aggressive brain cancer

HQ Team May 3, 2024: A vaccine using the mRNA technique combined with personalised delivery of tumor cells has been developed to combat.

Read More
A new weapon to kill superbugs may be on the horizon after Harvard researchers created a synthetic compound called cresomycin.
Drugs Health Pharma

Harvard researchers create superbug killer molecule cresomycin

 HQ Team February 20, 2024: A new weapon to kill superbugs may be on the horizon after researchers at the Cambridge, Massachusetts-based Harvard.

Read More
Hungarian-born biochemist Katalin Kariko and US immunologist Drew Weissman jointly won the Nobel Prize in Physiology or Medicine for their discoveries that led to the development of vaccines to fight the Covid-19 virus.
Drugs Health Pharma

Scientists behind Covid-19 mRNA vaccine bag Nobel medicine prize

HQ Team October 2, 2023: Hungarian-born biochemist Katalin Kariko and US immunologist Drew Weissman jointly won the Nobel Prize in Physiology or Medicine.

Read More
The US drug and medicine regulator, FDA, has approved COVID-19 vaccines made by Moderna Inc., Pfizer Inc., and BioNTech Manufacturing Gmb., to target new variants of the virus.
Drugs Health Pharma

USFDA green lights vaccines to fight COVID-19 variants in flu season

HQ Team September 12, 2023: The US drug and medicine regulator, the FDA, approved COVID-19 vaccines made by Moderna Inc., Pfizer Inc., and  BioNTech.

Read More
https://investors.immatics.com/news-releases/news-release-details/moderna-and-immatics-announce-strategic-multi-platform
Drugs Health Pharma

Moderna, Immatics join hands to hunt for cancer therapies using mRNA, AI 

HQ Team September 11, 2023: Moderna Inc. announced a pact with Immatics NV, a clinical-stage biopharmaceutical company, to develop cancer therapies using a.

Read More
Arbutus Biopharma Corporation and Genevant Sciences filed a lawsuit in a US court seeking compensation for Pfizer and BioNTech’s unlicensed use of its patents in making COVID-19 vaccines.
Drugs Health Medical Pharma

Arbutus drags Pfizer, BioNTech to court over patent infringements

HQ Team April 5, 2023: Arbutus Biopharma Corporation and Genevant Sciences filed a lawsuit in a US court seeking compensation for Pfizer and BioNTech’s unlicensed use.

Read More
Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received Breakthrough Therapy Designation from the USFDA.
Drugs Pharma

Moderna-Merck’s cancer vaccine gets FDA breakthrough therapy designation 

Moderna Inc., a biotechnology company, and Merck announced that an experimental personalised cancer vaccine, based on the messenger RNA (mRNA) technology, has received.

Read More